Publication name: Keep Well Interventions Overview Resource, Version 2 (2008 with added note on suspension of marketing license for Sibutramine in 2010)
Date: 30 March 2010
Description: The purpose of this resource is to provide an easily accessible overview of current 'guidelines' on action that can be taken by professionals and members of communities in pursuing the vision and focus of Keep Well.
Important added note: This resource (pages 29 and 30) refers to the drug Sibutramine in relation to the treatment of obesity in adults.

On 21 January 2010, the MHRA (Medicines and Healthcare products Regulatory Agency) announced that the marketing authorisation for Sibutramine (Reductil) has been suspended.
That announcement followed a review by the European Medicines Agency which found that the cardiovascular risks of Sibutramine outweigh its benefits.

The MHRA has issued the following advice to healthcare professionals and patients: Doctors should not issue any new prescriptions for Sibutramine, and should review the treatment of those who are currently taking this medicine.

Pharmacists should not dispense any prescriptions for Sibutramine and should
advise patients to make an appointment to see their doctor at the next convenient time.

Patients who are currently being treated with Sibutramine should be advised to schedule an appointment at the next convenient time with their doctor to discuss alternative measures to lose weight, including use of diet and exercise regimes.
Patients may stop treatment before their appointment if they wish.
View options: Download files

Alternative formats

If you require publications or documents in an alternative format such as large print, braille and audio versions, please contact Health Scotland publications –

We use cookies to help improve this website. You can change your cookie settings at any time. Otherwise, we'll assume you're OK to continue. Don't show this message again